🔗 Share this article

While the US proceeds with sweeping adjustments to its vaccine schedules, one figure appears unexpectedly: Høeg, a US-based physician and epidemiologist who initially gained attention by questioning COVID-19 vaccines during the pandemic and has zeroed in on possible fatalities after Covid immunization in her recent time at the Food and Drug Administration.

Scheduled Overhauls to Pediatric Immunization Program

Health officials had intended to reveal radical revisions to the pediatric vaccination calendar earlier this month, synchronizing the US with the Danish national calendar, according to reports – a major change that would put the US at odds with a large portion of the international standard with insufficient data for improved outcomes. This reveal has been delayed until the next year.

Instead of the director of the vaccine center, Høeg is set to speak at the meeting. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this year.

Consolidating Power at the Regulatory Body

This interim role might represent a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Prasad consolidate power at the agency – and it suggests a greater focus upon reevaluating already-approved vaccines at the FDA.

Høeg has frequently advocated for halting specific childhood vaccine recommendations in the US to become more like Denmark's approach, a country with nationalized medicine and a citizenry roughly the size of the state of Wisconsin.

In her initial statements, she has kept her attention on vaccination policy – traditionally the responsibility of Dr. Prasad, chief of the FDA’s CBER – rather than medication approval.

Doubts Over Background

Dr. Høeg has little discernible track record in medication creation, oversight or administrative roles, which has been standard for past directors of the CBER. She has worked at the FDA as a top consultant to the agency head and CBER since March.

“She doesn’t seem to have the necessary background” for leading the CDER, said a neurologist and psychiatrist. “She’s never run a clinical trial. She lacks experience in running a sizeable institution. She has no expertise in drug approvals.”

Previous commissioners of the center would “understand laws and regulations and the science of drug development”, noted Janet Woodcock. “Frankly, she lacks the sort of resume that previous people who led the center have had.”

The drug center has an vast workload at the agency, the former commissioner emphasized.

“Everybody just zeroes in on the novel medication approvals, but the generic drug division approves a multitude of generic drugs. There is also a biosimilars program, non-prescription drug unit and other areas, and all of those have to be looked after,” she said. “The area you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a significant leadership element to the position, which manages more than 5,000 employees. “It is a enormous management job, if you perform it correctly,” Woodcock added.

Official Statement and Controversial Programs

When asked about inquiries about Dr. Høeg's credentials and whether this appointment represents more teamwork among agency officials on vaccines, a representative responded that the “inquiries rely on flawed assumptions”.

“This background aligns with the responsibilities of her position,” the spokesperson said, pointing to the time Dr. Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a controversial expedited medication authorization process that allegedly troubled her predecessors. “How are these therapies being chosen for this fast-track system? Who takes the decisions?” Howard asked. “There is a lot of lack of transparency happening at the agency right now.”

Overall, he said, “the agency looks to be trending towards laxer oversight of all drugs, except for vaccines.”

Documented Past Work on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if concerning, history, critics have noted. She published a analysis using unconfirmed crowd-sourced reports to estimate the frequency of heart inflammation following Covid vaccination. She advised the Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccinations are pose a greater threat than they are.

Part of her “policy goals” for the incoming federal leadership featured changing rules for recently developed shots and halting “non-essential” immunizations, she remarked after the election on a online show. At the FDA, Dr. Høeg has according to sources proposed preventing young men from getting COVID-19 vaccines.

“She’s an all-around dogmatist who commences with her preconceived notions and tailors the evidence to fit the data in a extremely deceptive, untruthful way,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with other dissenters, {like|